Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571276 | 0.83 | — | — | |
| SCHEMBL20523242 | 0.79 | CXCR4 (0.40) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL3639333 | 0.77 | — | — | |
| SCHEMBL27172 | 0.77 | — | — | |
| SCHEMBL223380 | 0.76 | — | — | |
| SCHEMBL6353022 | 0.75 | — | — | |
| SCHEMBL73462 | 0.75 | — | — | |
| Taurultam SCHEMBL428345 | 0.75 | — | — | |
| SCHEMBL21508069 | 0.72 | ADRA2B (0.31) | ALDH1A1 | |
| SCHEMBL17319677 | 0.72 | ADRA2B (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012467-B2 | Small molecule DCN1 inhibitors and therapeutic methods using the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-18 | — | — | US | disclosed |
| EP-3609876-B1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20200109167-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3609876-A1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3601245-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018191199-A1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20180289677-A1 | Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-10-11 | — | — | US | disclosed |
| WO-2018183411-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289677-A1 | Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same | CAPNS1, DCLRE1A, DCUN1D2 | CXCR4 4618/4885SMN1; SMN2 25/4885ALDH1A1 2515/4885 |
| US-20200109167-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | DCUN1D2, CLN6, CAPNS1 | CXCR4 4716/4885SMN1; SMN2 9/4885ALDH1A1 2290/4885 |
| US-12012467-B2 | Small molecule DCN1 inhibitors and therapeutic methods using the same | DCUN1D2, CLN6, CAPNS1 | CXCR4 4716/4885SMN1; SMN2 9/4885ALDH1A1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.